Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNA ME-TRAP + MVA ME-TRAP
- Development stage
- Discontinued
- Lead developer
- University of Oxford
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
DNA ME-TRAP + MVA ME-TRAP is an investigational heterologous prime-boost malaria vaccine regimen. It consists of two distinct components: a plasmid DNA priming vaccine and a Modified Vaccinia virus Ankara (MVA) boosting vaccine. Both components encode the same recombinant antigen, ME-TRAP, which is a fusion of a multiple epitope (ME) string and the Thrombospondin-Related Adhesion Protein (TRAP) from the pre-erythrocytic sporozoite stage of *Plasmodium falciparum*. The regimen is designed to induce high-frequency effector T cell responses (specifically CD8+ and CD4+ T cells) against the liver stage of the malaria parasite to prevent progression to symptomatic disease. Developed by the London School of Hygiene and Tropical Medicine in collaboration with the University of Oxford, the vaccine was evaluated in clinical trials in West Africa but failed to demonstrate significant protective efficacy against natural infection in semi-immune adults.
- Other names
- ME-TRAP vaccineDNA/MVA ME-TRAPDNA-MVA ME-TRAP
02
Targets
TRAP (Thrombospondin-related anonymous protein)
Beyond the preview
Go deeper on DNA ME-TRAP + MVA ME-TRAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA ME-TRAP + MVA ME-TRAP.